Annexon stock spikes on data for GBS therapy (NASDAQ:ANNX)
Md Saiful Islam Khan/iStock via Getty Images Annexon (NASDAQ:ANNX) shares traded higher on Wednesday after the company released additional data from its completed pivotal Phase 3 trial for its lead asset, ANX005, against the neurological disorder Guillain-Barré syndrome (GBS). Early this month, citing topline results from the study, the Brisbane,Continue Reading